During this period, the NCGC has completed primary screening for ALDH1A1 inhibitors, and medicinal chemistry of lead chemotypes is currently underway. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
| Yang, Shyh-Ming; Martinez, Natalia J; Yasgar, Adam et al. (2018) Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. J Med Chem 61:4883-4903 |
| Yasgar, Adam; Titus, Steven A; Wang, Yuhong et al. (2018) Correction: A High-Content Assay Enables the Automated Screening and Identification of Small Molecules with Specific ALDH1A1-Inhibitory Activity. PLoS One 13:e0197292 |
| Yasgar, Adam; Titus, Steven A; Wang, Yuhong et al. (2017) A High-Content Assay Enables the Automated Screening and Identification of Small Molecules with Specific ALDH1A1-Inhibitory Activity. PLoS One 12:e0170937 |
